TipRanks on MSN

C4 Therapeutics Reports Promising Phase 1 Trial Results

The latest announcement is out from C4 Therapeutics ( (CCCC) ).

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the ...
Nasdaq

C4 Therapeutics Reports Promising Cemsidomide Data in Multiple Myeloma and Announces Strategic Development Priorities

C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...
TMCnet

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM ... additional detail on the company’s planned next steps of clinical development. C4 Therapeutics (C4T) ...
TipRanks on MSN

C4 Therapeutics initiated with an Overweight at Barclays

Barclays initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $8 price target The company’s lead asset, cemsidomide is an ...